World Hypopara Awareness Day is June 1!
Join us in raising awareness for people living with hypoparathyroidism and share this link.

Advancing peptides for the treatment of rare endocrine and related diseases

We are a clinical stage, global company, building on our team’s established expertise to transform the lives of patients living with rare endocrine and related diseases.



Our lead clinical candidate is a potentially clinically superior therapeutic peptide in development for hypoparathyroidism.


AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development for acromegaly.

AZP-3813 Acromegal


Our management team has the collective and proven expertise necessary to advance its portfolio of innovative therapies in the clinic.

Press Releases & Recent News

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

Download a PDF copy of this press release: EN FR Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as …

Read More →
Download a PDF: EN or FR

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group

Download a PDF copy of this press release: EN FR Funds will be used to complete phase 3 clinical development …

Read More →
Download a PDF: EN or FR

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.

Scroll to Top